Bridging Innovation and Accessibility in Healthcare
Hey there! Welcome to this week’s edition of The Value Science Weekly, where we explore the latest intersections of healthcare, economics, and technology shaping the future of medical access and value. This week, we’re featuring two articles that tackle "emerging markets in healthcare and advancements in personalised therapies."
Today’s question for you to ponder: How can we balance the introduction of innovative healthcare treatments like lenacapavir with the need for cost-effective thresholds in health economics?
Editor’s Pick 1: “Lenacapavir Injection: A Breakthrough in Global HIV Prevention”
In our first article, we look into the transformative potential of lenacapavir injections in combating HIV. The PURPOSE 1 trial showed no new infections among young African women receiving these twice-yearly injections. Globally, the PURPOSE 2 trial demonstrated a 96% efficacy rate, significantly surpassing daily oral medications like Truvada. This breakthrough could be transformative for populations who struggle with daily medication adherence. The World Health Organization is working on guidelines to ensure global access to this innovative treatment. However, challenges such as temporary FDA holds and participant eligibility issues remain. How can we overcome these challenges to maximise lenacapavir's impact? And what strategies can be implemented to ensure equitable access to this groundbreaking medication worldwide?
Editor’s Pick 2: “Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate”
Our second feature explores the ongoing debate regarding NICE’s cost-effectiveness thresholds. Critics argue that QALYs, a key metric, may not fully capture the complexity of health outcomes. NICE traditionally uses a threshold range of ￡20,000 to ￡30,000 per QALY gained. The static nature of this threshold could hinder investment in innovative healthcare technologies. Adjusting thresholds to reflect economic growth and societal values could enhance their relevance. Despite debates, NICE has maintained a high rate of positive recommendations for new technologies. How should cost-effectiveness thresholds evolve to better support innovation? And what role should societal values and patient needs play in shaping these thresholds?
HEOR Perspectives on Innovation
领英推荐
DiaCision?:Dynamic Decisions for Diabetes
Download our whitepaper to learn how DiaCision? can transform diabetes management with dynamic insights and AI-powered solutions, driving better outcomes for patients and systems alike.
Would you like The Value Science Weekly on email? Subscribe here: